LEF1 and acute myeloid leukemia: For lymphoid enhancer-binding factor-1 (LEF1) it was shown that high gene expression levels are associated with favourable clinical outcome in CN-AML [13], and thus that downregulated expression levels are then associated with unfavourable clinical outcome.